-
1
-
-
79954571305
-
Myeloid blastic transformation of myeloproliferative neoplasms-a review of 112 cases
-
Noor S. J., Tan W., Wilding G. E., et al. Myeloid blastic transformation of myeloproliferative neoplasms-a review of 112 cases. Leuk Res: 2011; 35 5 608 613
-
(2011)
Leuk Res
, vol.35
, Issue.5
, pp. 608-613
-
-
Noor, S.J.1
Tan, W.2
Wilding, G.E.3
-
2
-
-
0031046884
-
The very long-term evolution of polycythemia vera: An analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981
-
Najean Y., Rain J. D. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol: 1997; 34 1 6 16
-
(1997)
Semin Hematol
, vol.34
, Issue.1
, pp. 6-16
-
-
Najean, Y.1
Rain, J.D.2
-
3
-
-
80051803115
-
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study
-
Barbui T., Thiele J., Passamonti F., et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol: 2011; 29 23 3179 3184
-
(2011)
J Clin Oncol
, vol.29
, Issue.23
, pp. 3179-3184
-
-
Barbui, T.1
Thiele, J.2
Passamonti, F.3
-
4
-
-
84856946984
-
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management
-
Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol: 2012; 87 3 285 293
-
(2012)
Am J Hematol
, vol.87
, Issue.3
, pp. 285-293
-
-
Tefferi, A.1
-
5
-
-
77953068974
-
A retrospective study on 226 polycythemia vera patients: Impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs
-
Crisà E., Venturino E., Passera R., et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol: 2010; 89 7 691 699
-
(2010)
Ann Hematol
, vol.89
, Issue.7
, pp. 691-699
-
-
Crisà, E.1
Venturino, E.2
Passera, R.3
-
6
-
-
43549125836
-
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
-
Passamonti F., Rumi E., Caramella M., et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood: 2008; 111 7 3383 3387
-
(2008)
Blood
, vol.111
, Issue.7
, pp. 3383-3387
-
-
Passamonti, F.1
Rumi, E.2
Caramella, M.3
-
7
-
-
77949328094
-
Thrombosis in primary myelofibrosis: Incidence and risk factors
-
Barbui T., Carobbio A., Cervantes F., et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood: 2010; 115 4 778 782
-
(2010)
Blood
, vol.115
, Issue.4
, pp. 778-782
-
-
Barbui, T.1
Carobbio, A.2
Cervantes, F.3
-
8
-
-
34249949626
-
Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F
-
Tefferi A., Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost: 2007; 33 4 313 320
-
(2007)
Semin Thromb Hemost
, vol.33
, Issue.4
, pp. 313-320
-
-
Tefferi, A.1
Elliott, M.2
-
9
-
-
80055121148
-
Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms
-
Hoekstra J., Bresser E. L., Smalberg J. H., Spaander M. C., Leebeek F. W., Janssen H. L. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J Thromb Haemost: 2011; 9 11 2208 2214
-
(2011)
J Thromb Haemost
, vol.9
, Issue.11
, pp. 2208-2214
-
-
Hoekstra, J.1
Bresser, E.L.2
Smalberg, J.H.3
Spaander, M.C.4
Leebeek, F.W.5
Janssen, H.L.6
-
10
-
-
84859631134
-
Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera
-
Reikvam H., Tiu R. V. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia: 2012; 26 4 563 571
-
(2012)
Leukemia
, vol.26
, Issue.4
, pp. 563-571
-
-
Reikvam, H.1
Tiu, R.V.2
-
11
-
-
68249099452
-
Etiology, management, and outcome of the Budd-Chiari syndrome
-
EN-Vie (European Network for Vascular Disorders of the Liver)
-
Darwish Murad S., Plessier A., Hernandez-Guerra M., et al. EN-Vie (European Network for Vascular Disorders of the Liver) Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med: 2009; 151 3 167 175
-
(2009)
Ann Intern Med
, vol.151
, Issue.3
, pp. 167-175
-
-
Darwish Murad, S.1
Plessier, A.2
Hernandez-Guerra, M.3
-
12
-
-
34147156839
-
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders
-
De Stefano V., Fiorini A., Rossi E., et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost: 2007; 5 4 708 714
-
(2007)
J Thromb Haemost
, vol.5
, Issue.4
, pp. 708-714
-
-
De Stefano, V.1
Fiorini, A.2
Rossi, E.3
-
13
-
-
33845546565
-
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis
-
Colaizzo D., Amitrano L., Tiscia G. L., et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost: 2007; 5 1 55 61
-
(2007)
J Thromb Haemost
, vol.5
, Issue.1
, pp. 55-61
-
-
Colaizzo, D.1
Amitrano, L.2
Tiscia, G.L.3
-
14
-
-
46749132374
-
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: A report on 241 cases
-
Kiladjian J. J., Cervantes F., Leebeek F. W., et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood: 2008; 111 10 4922 4929
-
(2008)
Blood
, vol.111
, Issue.10
, pp. 4922-4929
-
-
Kiladjian, J.J.1
Cervantes, F.2
Leebeek, F.W.3
-
15
-
-
67049173799
-
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: A meta-analysis
-
Dentali F., Squizzato A., Brivio L., et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood: 2009; 113 22 5617 5623
-
(2009)
Blood
, vol.113
, Issue.22
, pp. 5617-5623
-
-
Dentali, F.1
Squizzato, A.2
Brivio, L.3
-
16
-
-
77957779176
-
Thrombosis in myelofibrosis: Prior thrombosis is the only predictive factor and most venous events are provoked
-
Elliott M. A., Pardanani A., Lasho T. L., Schwager S. M., Tefferi A. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica: 2010; 95 10 1788 1791
-
(2010)
Haematologica
, vol.95
, Issue.10
, pp. 1788-1791
-
-
Elliott, M.A.1
Pardanani, A.2
Lasho, T.L.3
Schwager, S.M.4
Tefferi, A.5
-
17
-
-
20244389579
-
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
-
Marchioli R., Finazzi G., Landolfi R., et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol: 2005; 23 10 2224 2232
-
(2005)
J Clin Oncol
, vol.23
, Issue.10
, pp. 2224-2232
-
-
Marchioli, R.1
Finazzi, G.2
Landolfi, R.3
-
18
-
-
21444434751
-
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
-
United Kingdom Medical Research Council Primary Thrombocythemia 1 Study
-
Harrison C. N., Campbell P. J., Buck G., et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med: 2005; 353 1 33 45
-
(2005)
N Engl J Med
, vol.353
, Issue.1
, pp. 33-45
-
-
Harrison, C.N.1
Campbell, P.J.2
Buck, G.3
-
19
-
-
40849085151
-
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments
-
GIMEMA CMD-Working Party
-
De Stefano V., Za T., Rossi E., et al. GIMEMA CMD-Working Party Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica: 2008; 93 3 372 380
-
(2008)
Haematologica
, vol.93
, Issue.3
, pp. 372-380
-
-
De Stefano, V.1
Za, T.2
Rossi, E.3
-
20
-
-
0029847674
-
Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation
-
van Genderen P. J., Lucas I. S., van Strik R., et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost: 1996; 76 3 333 338
-
(1996)
Thromb Haemost
, vol.76
, Issue.3
, pp. 333-338
-
-
Van Genderen, P.J.1
Lucas, I.S.2
Van Strik, R.3
-
21
-
-
0016738658
-
Platelet function in patients with high platelet counts
-
Ginsburg A. D. Platelet function in patients with high platelet counts. Ann Intern Med: 1975; 82 4 506 511
-
(1975)
Ann Intern Med
, vol.82
, Issue.4
, pp. 506-511
-
-
Ginsburg, A.D.1
-
22
-
-
0033871736
-
Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders
-
Jensen M. K., de Nully Brown P., Lund B. V., Nielsen O. J., Hasselbalch H. C. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol: 2000; 110 1 116 124
-
(2000)
Br J Haematol
, vol.110
, Issue.1
, pp. 116-124
-
-
Jensen, M.K.1
De Nully Brown, P.2
Lund, B.V.3
Nielsen, O.J.4
Hasselbalch, H.C.5
-
23
-
-
0026808372
-
Increased thromboxane biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo
-
Landolfi R., Ciabattoni G., Patrignani P., et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood: 1992; 80 8 1965 1971
-
(1992)
Blood
, vol.80
, Issue.8
, pp. 1965-1971
-
-
Landolfi, R.1
Ciabattoni, G.2
Patrignani, P.3
-
24
-
-
0028809443
-
Increased thromboxane biosynthesis in essential thrombocythemia
-
Rocca B., Ciabattoni G., Tartaglione R., et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost: 1995; 74 5 1225 1230
-
(1995)
Thromb Haemost
, vol.74
, Issue.5
, pp. 1225-1230
-
-
Rocca, B.1
Ciabattoni, G.2
Tartaglione, R.3
-
25
-
-
51649130509
-
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients
-
Santilli F., Romano M., Recchiuti A., et al. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood: 2008; 112 4 1085 1090
-
(2008)
Blood
, vol.112
, Issue.4
, pp. 1085-1090
-
-
Santilli, F.1
Romano, M.2
Recchiuti, A.3
-
26
-
-
0018181405
-
Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia
-
Pearson T. C., Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet: 1978; 2 8102 1219 1222
-
(1978)
Lancet
, vol.2
, Issue.8102
, pp. 1219-1222
-
-
Pearson, T.C.1
Wetherley-Mein, G.2
-
27
-
-
17844390356
-
Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera
-
Falanga A., Marchetti M., Vignoli A., Balducci D., Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol: 2005; 33 5 523 530
-
(2005)
Exp Hematol
, vol.33
, Issue.5
, pp. 523-530
-
-
Falanga, A.1
Marchetti, M.2
Vignoli, A.3
Balducci, D.4
Barbui, T.5
-
28
-
-
67649402606
-
Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: Is leukocytosis a causative factor
-
Barbui T., Carobbio A., Rambaldi A., Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood: 2009; 114 4 759 763
-
(2009)
Blood
, vol.114
, Issue.4
, pp. 759-763
-
-
Barbui, T.1
Carobbio, A.2
Rambaldi, A.3
Finazzi, G.4
-
29
-
-
34447619693
-
Platelet and coagulation activation markers in myeloproliferative diseases: Relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies
-
Robertson B., Urquhart C., Ford I., et al. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies. J Thromb Haemost: 2007; 5 8 1679 1685
-
(2007)
J Thromb Haemost
, vol.5
, Issue.8
, pp. 1679-1685
-
-
Robertson, B.1
Urquhart, C.2
Ford, I.3
-
30
-
-
34547952655
-
Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM
-
Wautier M. P., El Nemer W., Gane P., et al. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM. Blood: 2007; 110 3 894 901
-
(2007)
Blood
, vol.110
, Issue.3
, pp. 894-901
-
-
Wautier, M.P.1
El Nemer, W.2
Gane, P.3
-
31
-
-
48449088506
-
Microparticles in vascular diseases
-
01
-
George F. D. Microparticles in vascular diseases. Thromb Res: 2008; 122 01 S55 S59
-
(2008)
Thromb Res
, vol.122
-
-
George, F.D.1
-
32
-
-
67650727986
-
Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia
-
Trappenburg M. C., van Schilfgaarde M., Marchetti M., et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica: 2009; 94 7 911 918
-
(2009)
Haematologica
, vol.94
, Issue.7
, pp. 911-918
-
-
Trappenburg, M.C.1
Van Schilfgaarde, M.2
Marchetti, M.3
-
33
-
-
78149284944
-
Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosis
-
Moles-Moreau M. P., Ternisien C., Tanguy-Schmidt A., et al. Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosis. Thromb Res: 2010; 126 5 e394 e396
-
(2010)
Thromb Res
, vol.126
, Issue.5
-
-
Moles-Moreau, M.P.1
Ternisien, C.2
Tanguy-Schmidt, A.3
-
34
-
-
77956268837
-
Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms
-
Duchemin J., Ugo V., Ianotto J. C., Lecucq L., Mercier B., Abgrall J. F. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res: 2010; 126 3 238 242
-
(2010)
Thromb Res
, vol.126
, Issue.3
, pp. 238-242
-
-
Duchemin, J.1
Ugo, V.2
Ianotto, J.C.3
Lecucq, L.4
Mercier, B.5
Abgrall, J.F.6
-
35
-
-
67149133738
-
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome
-
Sozer S., Fiel M. I., Schiano T., Xu M., Mascarenhas J., Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood: 2009; 113 21 5246 5249
-
(2009)
Blood
, vol.113
, Issue.21
, pp. 5246-5249
-
-
Sozer, S.1
Fiel, M.I.2
Schiano, T.3
Xu, M.4
Mascarenhas, J.5
Hoffman, R.6
-
36
-
-
79953071111
-
Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms
-
Teofili L., Martini M., Iachininoto M. G., et al. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood: 2011; 117 9 2700 2707
-
(2011)
Blood
, vol.117
, Issue.9
, pp. 2700-2707
-
-
Teofili, L.1
Martini, M.2
Iachininoto, M.G.3
-
37
-
-
28244442441
-
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study
-
United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group
-
Campbell P. J., Scott L. M., Buck G., et al. United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet: 2005; 366 9501 1945 1953
-
(2005)
Lancet
, vol.366
, Issue.9501
, pp. 1945-1953
-
-
Campbell, P.J.1
Scott, L.M.2
Buck, G.3
-
38
-
-
68549136745
-
JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera
-
Carobbio A., Finazzi G., Antonioli E., et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol: 2009; 37 9 1016 1021
-
(2009)
Exp Hematol
, vol.37
, Issue.9
, pp. 1016-1021
-
-
Carobbio, A.1
Finazzi, G.2
Antonioli, E.3
-
39
-
-
68549116852
-
Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review
-
Lussana F., Caberlon S., Pagani C., Kamphuisen P. W., Büller H. R., Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res: 2009; 124 4 409 417
-
(2009)
Thromb Res
, vol.124
, Issue.4
, pp. 409-417
-
-
Lussana, F.1
Caberlon, S.2
Pagani, C.3
Kamphuisen, P.W.4
Büller, H.R.5
Cattaneo, M.6
-
40
-
-
34547953018
-
Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia
-
Vannucchi A. M., Antonioli E., Guglielmelli P., et al. Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia. Blood: 2007; 110 3 840 846
-
(2007)
Blood
, vol.110
, Issue.3
, pp. 840-846
-
-
Vannucchi, A.M.1
Antonioli, E.2
Guglielmelli, P.3
-
41
-
-
34548136101
-
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden
-
MPD Research Consortium
-
Vannucchi A. M., Antonioli E., Guglielmelli P., et al. MPD Research Consortium Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia: 2007; 21 9 1952 1959
-
(2007)
Leukemia
, vol.21
, Issue.9
, pp. 1952-1959
-
-
Vannucchi, A.M.1
Antonioli, E.2
Guglielmelli, P.3
-
42
-
-
38549135526
-
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia
-
Myeloproliferative Disorders Research Consortium (MPD-RC)
-
Antonioli E., Guglielmelli P., Poli G., et al. Myeloproliferative Disorders Research Consortium (MPD-RC) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica: 2008; 93 1 41 48
-
(2008)
Haematologica
, vol.93
, Issue.1
, pp. 41-48
-
-
Antonioli, E.1
Guglielmelli, P.2
Poli, G.3
-
43
-
-
79551607979
-
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
-
Passamonti F., Elena C., Schnittger S., et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood: 2011; 117 10 2813 2816
-
(2011)
Blood
, vol.117
, Issue.10
, pp. 2813-2816
-
-
Passamonti, F.1
Elena, C.2
Schnittger, S.3
-
44
-
-
50949127379
-
Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia
-
Vannucchi A. M., Antonioli E., Guglielmelli P., et al. Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia. Blood: 2008; 112 3 844 847
-
(2008)
Blood
, vol.112
, Issue.3
, pp. 844-847
-
-
Vannucchi, A.M.1
Antonioli, E.2
Guglielmelli, P.3
-
45
-
-
47249092413
-
MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort
-
Beer P. A., Campbell P. J., Scott L. M., et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood: 2008; 112 1 141 149
-
(2008)
Blood
, vol.112
, Issue.1
, pp. 141-149
-
-
Beer, P.A.1
Campbell, P.J.2
Scott, L.M.3
-
46
-
-
67349124376
-
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
-
Tefferi A., Pardanani A., Lim K. H., et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia: 2009; 23 5 905 911
-
(2009)
Leukemia
, vol.23
, Issue.5
, pp. 905-911
-
-
Tefferi, A.1
Pardanani, A.2
Lim, K.H.3
-
47
-
-
84858062280
-
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
-
Barbui T., Thiele J., Passamonti F., et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood: 2012; 119 10 2239 2241
-
(2012)
Blood
, vol.119
, Issue.10
, pp. 2239-2241
-
-
Barbui, T.1
Thiele, J.2
Passamonti, F.3
-
48
-
-
79551644817
-
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: Different role of C-reactive protein and pentraxin 3
-
AGIMM and IIC Investigators
-
Barbui T., Carobbio A., Finazzi G., et al. AGIMM and IIC Investigators Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica: 2011; 96 2 315 318
-
(2011)
Haematologica
, vol.96
, Issue.2
, pp. 315-318
-
-
Barbui, T.1
Carobbio, A.2
Finazzi, G.3
-
49
-
-
79551491928
-
Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet
-
European LeukemiaNet
-
Barbui T., Barosi G., Birgegard G., et al. European LeukemiaNet Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol: 2011; 29 6 761 770
-
(2011)
J Clin Oncol
, vol.29
, Issue.6
, pp. 761-770
-
-
Barbui, T.1
Barosi, G.2
Birgegard, G.3
-
50
-
-
79952075257
-
Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies
-
Tefferi A., Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol: 2011; 29 5 573 582
-
(2011)
J Clin Oncol
, vol.29
, Issue.5
, pp. 573-582
-
-
Tefferi, A.1
Vainchenker, W.2
-
51
-
-
0028844554
-
Polycythemia vera: The natural history of 1213 patients followed for 20 years
-
Gruppo Italiano Studio Policitemia
-
Gruppo Italiano Studio Policitemia Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med: 1995; 123 9 656 664
-
(1995)
Ann Intern Med
, vol.123
, Issue.9
, pp. 656-664
-
-
-
52
-
-
34848858920
-
Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia
-
Radaelli F., Colombi M., Calori R., et al. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia. Hematol Oncol: 2007; 25 3 115 120
-
(2007)
Hematol Oncol
, vol.25
, Issue.3
, pp. 115-120
-
-
Radaelli, F.1
Colombi, M.2
Calori, R.3
-
53
-
-
0346727336
-
Efficacy and safety of low-dose aspirin in polycythemia vera
-
European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators
-
Landolfi R., Marchioli R., Kutti J., et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med: 2004; 350 2 114 124
-
(2004)
N Engl J Med
, vol.350
, Issue.2
, pp. 114-124
-
-
Landolfi, R.1
Marchioli, R.2
Kutti, J.3
-
54
-
-
33749351784
-
Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; Does number matter
-
Tefferi A., Gangat N., Wolanskyj A. P. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood: 2006; 108 7 2493 2494
-
(2006)
Blood
, vol.108
, Issue.7
, pp. 2493-2494
-
-
Tefferi, A.1
Gangat, N.2
Wolanskyj, A.P.3
-
55
-
-
84865229049
-
Correlation of blood counts with vascular complications in essential thrombocythemia: Analysis of the prospective PT1 cohort
-
Campbell P. J., MacLean C., Beer P. A., et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood: 2012; 120 7 1409 1411
-
(2012)
Blood
, vol.120
, Issue.7
, pp. 1409-1411
-
-
Campbell, P.J.1
MacLean, C.2
Beer, P.A.3
-
56
-
-
32144461605
-
Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors
-
Wolanskyj A. P., Schwager S. M., McClure R. F., Larson D. R., Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc: 2006; 81 2 159 166
-
(2006)
Mayo Clin Proc
, vol.81
, Issue.2
, pp. 159-166
-
-
Wolanskyj, A.P.1
Schwager, S.M.2
McClure, R.F.3
Larson, D.R.4
Tefferi, A.5
-
57
-
-
33947208087
-
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
-
European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP)
-
Landolfi R., Di Gennaro L., Barbui T., et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood: 2007; 109 6 2446 2452
-
(2007)
Blood
, vol.109
, Issue.6
, pp. 2446-2452
-
-
Landolfi, R.1
Di Gennaro, L.2
Barbui, T.3
-
58
-
-
75449098063
-
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia
-
GIMEMA Chronic Myeloproliferative Neoplasms Working Party
-
De Stefano V., Za T., Rossi E., et al. GIMEMA Chronic Myeloproliferative Neoplasms Working Party Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol: 2010; 85 2 97 100
-
(2010)
Am J Hematol
, vol.85
, Issue.2
, pp. 97-100
-
-
De Stefano, V.1
Za, T.2
Rossi, E.3
-
59
-
-
84862518266
-
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients
-
Buxhofer-Ausch V., Gisslinger H., Thiele J., et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol: 2012; 87 7 669 672
-
(2012)
Am J Hematol
, vol.87
, Issue.7
, pp. 669-672
-
-
Buxhofer-Ausch, V.1
Gisslinger, H.2
Thiele, J.3
-
60
-
-
0034672149
-
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera
-
Falanga A., Marchetti M., Evangelista V., et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood: 2000; 96 13 4261 4266
-
(2000)
Blood
, vol.96
, Issue.13
, pp. 4261-4266
-
-
Falanga, A.1
Marchetti, M.2
Evangelista, V.3
-
61
-
-
73149090129
-
Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera
-
Gangat N., Wolanskyj A. P., Schwager S. M., Hanson C. A., Tefferi A. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer: 2009; 115 24 5740 5745
-
(2009)
Cancer
, vol.115
, Issue.24
, pp. 5740-5745
-
-
Gangat, N.1
Wolanskyj, A.P.2
Schwager, S.M.3
Hanson, C.A.4
Tefferi, A.5
-
62
-
-
78149470436
-
Thrombohemorrhagic complications of myeloproliferative disorders
-
Papadakis E., Hoffman R., Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev: 2010; 24 6 227 232
-
(2010)
Blood Rev
, vol.24
, Issue.6
, pp. 227-232
-
-
Papadakis, E.1
Hoffman, R.2
Brenner, B.3
-
63
-
-
0036735354
-
Factor v Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia
-
Ruggeri M., Gisslinger H., Tosetto A., et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol: 2002; 71 1 1 6
-
(2002)
Am J Hematol
, vol.71
, Issue.1
, pp. 1-6
-
-
Ruggeri, M.1
Gisslinger, H.2
Tosetto, A.3
-
64
-
-
15244363669
-
Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: A cohort study
-
Gisslinger H., Müllner M., Pabinger I., et al. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study. Haematologica: 2005; 90 3 408 410
-
(2005)
Haematologica
, vol.90
, Issue.3
, pp. 408-410
-
-
Gisslinger, H.1
Müllner, M.2
Pabinger, I.3
-
65
-
-
0022743990
-
Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera
-
Tartaglia A. P., Goldberg J. D., Berk P. D., Wasserman L. R. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol: 1986; 23 3 172 176
-
(1986)
Semin Hematol
, vol.23
, Issue.3
, pp. 172-176
-
-
Tartaglia, A.P.1
Goldberg, J.D.2
Berk, P.D.3
Wasserman, L.R.4
-
66
-
-
84983134916
-
Low-dose aspirin in polycythaemia vera: A pilot study
-
Gruppo Italiano Studio Policitemia (GISP)
-
Gruppo Italiano Studio Policitemia (GISP) Low-dose aspirin in polycythaemia vera: a pilot study. Br J Haematol: 1997; 97 2 453 456
-
(1997)
Br J Haematol
, vol.97
, Issue.2
, pp. 453-456
-
-
-
67
-
-
77956524019
-
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
-
quiz 1387
-
Alvarez-Larrán A., Cervantes F., Pereira A., et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood: 2010; 116 8 1205 1210, quiz 1387
-
(2010)
Blood
, vol.116
, Issue.8
, pp. 1205-1210
-
-
Alvarez-Larrán, A.1
Cervantes, F.2
Pereira, A.3
-
68
-
-
84856946984
-
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management
-
Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol: 2012; 87 3 285 293
-
(2012)
Am J Hematol
, vol.87
, Issue.3
, pp. 285-293
-
-
Tefferi, A.1
-
70
-
-
84859856401
-
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
-
Pascale S., Petrucci G., Dragani A., et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood: 2012; 119 15 3595 3603
-
(2012)
Blood
, vol.119
, Issue.15
, pp. 3595-3603
-
-
Pascale, S.1
Petrucci, G.2
Dragani, A.3
-
71
-
-
0019378211
-
Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy
-
Berk P. D., Goldberg J. D., Silverstein M. N., et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med: 1981; 304 8 441 447
-
(1981)
N Engl J Med
, vol.304
, Issue.8
, pp. 441-447
-
-
Berk, P.D.1
Goldberg, J.D.2
Silverstein, M.N.3
-
72
-
-
0022703490
-
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols
-
Berk P. D., Goldberg J. D., Donovan P. B., Fruchtman S. M., Berlin N. I., Wasserman L. R. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol: 1986; 23 2 132 143
-
(1986)
Semin Hematol
, vol.23
, Issue.2
, pp. 132-143
-
-
Berk, P.D.1
Goldberg, J.D.2
Donovan, P.B.3
Fruchtman, S.M.4
Berlin, N.I.5
Wasserman, L.R.6
-
73
-
-
33845900474
-
The haematocrit and platelet target in polycythemia vera
-
European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators
-
Di Nisio M., Barbui T., Di Gennaro L., et al. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators The haematocrit and platelet target in polycythemia vera. Br J Haematol: 2007; 136 2 249 259
-
(2007)
Br J Haematol
, vol.136
, Issue.2
, pp. 249-259
-
-
Di Nisio, M.1
Barbui, T.2
Di Gennaro, L.3
-
74
-
-
84859633059
-
The CYTO-PV: A large-scale trial testing the intensity of cytoreductive therapy to prevent cardiovascular events in patients with polycythemia vera
-
Marchioli R., Finazzi G., Specchia G., Masciulli A., Mennitto M. R., Barbui T. The CYTO-PV: A large-scale trial testing the intensity of cytoreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis: 2011; 2011 794240
-
(2011)
Thrombosis
, vol.2011
, pp. 794240
-
-
Marchioli, R.1
Finazzi, G.2
Specchia, G.3
Masciulli, A.4
Mennitto, M.R.5
Barbui, T.6
-
75
-
-
0028913012
-
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
-
Cortelazzo S., Finazzi G., Ruggeri M., et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med: 1995; 332 17 1132 1136
-
(1995)
N Engl J Med
, vol.332
, Issue.17
, pp. 1132-1136
-
-
Cortelazzo, S.1
Finazzi, G.2
Ruggeri, M.3
-
76
-
-
79959203501
-
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms
-
Björkholm M., Derolf A. R., Hultcrantz M., et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol: 2011; 29 17 2410 2415
-
(2011)
J Clin Oncol
, vol.29
, Issue.17
, pp. 2410-2415
-
-
Björkholm, M.1
Derolf, A.R.2
Hultcrantz, M.3
-
77
-
-
8344229870
-
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
-
Passamonti F., Rumi E., Pungolino E., et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med: 2004; 117 10 755 761
-
(2004)
Am J Med
, vol.117
, Issue.10
, pp. 755-761
-
-
Passamonti, F.1
Rumi, E.2
Pungolino, E.3
-
78
-
-
56249104095
-
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms
-
Kiladjian J. J., Chomienne C., Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia: 2008; 22 11 1990 1998
-
(2008)
Leukemia
, vol.22
, Issue.11
, pp. 1990-1998
-
-
Kiladjian, J.J.1
Chomienne, C.2
Fenaux, P.3
-
79
-
-
33746307253
-
Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha
-
Silver R. T. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer: 2006; 107 3 451 458
-
(2006)
Cancer
, vol.107
, Issue.3
, pp. 451-458
-
-
Silver, R.T.1
-
80
-
-
73949090770
-
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
-
Quintás-Cardama A., Kantarjian H., Manshouri T., et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol: 2009; 27 32 5418 5424
-
(2009)
J Clin Oncol
, vol.27
, Issue.32
, pp. 5418-5424
-
-
Quintás-Cardama, A.1
Kantarjian, H.2
Manshouri, T.3
-
81
-
-
54049141336
-
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
-
Kiladjian J. J., Cassinat B., Chevret S., et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood: 2008; 112 8 3065 3072
-
(2008)
Blood
, vol.112
, Issue.8
, pp. 3065-3072
-
-
Kiladjian, J.J.1
Cassinat, B.2
Chevret, S.3
-
82
-
-
0037217859
-
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia
-
Alvarado Y., Cortes J., Verstovsek S., et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol: 2003; 51 1 81 86
-
(2003)
Cancer Chemother Pharmacol
, vol.51
, Issue.1
, pp. 81-86
-
-
Alvarado, Y.1
Cortes, J.2
Verstovsek, S.3
-
83
-
-
27144539129
-
Pegylated interferon for the treatment of high risk essential thrombocythemia: Results of a phase II study
-
Langer C., Lengfelder E., Thiele J., et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica: 2005; 90 10 1333 1338
-
(2005)
Haematologica
, vol.90
, Issue.10
, pp. 1333-1338
-
-
Langer, C.1
Lengfelder, E.2
Thiele, J.3
-
84
-
-
33646470836
-
A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: Feasibility, clinical and biologic effects, and impact on quality of life
-
Nordic Study Group for Myeloproliferative Disorders
-
Samuelsson J., Hasselbalch H., Bruserud O., et al. Nordic Study Group for Myeloproliferative Disorders A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer: 2006; 106 11 2397 2405
-
(2006)
Cancer
, vol.106
, Issue.11
, pp. 2397-2405
-
-
Samuelsson, J.1
Hasselbalch, H.2
Bruserud, O.3
-
85
-
-
84863393110
-
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
-
Verstovsek S., Mesa R. A., Gotlib J., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med: 2012; 366 9 799 807
-
(2012)
N Engl J Med
, vol.366
, Issue.9
, pp. 799-807
-
-
Verstovsek, S.1
Mesa, R.A.2
Gotlib, J.3
-
86
-
-
77956696835
-
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
-
Verstovsek S., Kantarjian H., Mesa R. A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med: 2010; 363 12 1117 1127
-
(2010)
N Engl J Med
, vol.363
, Issue.12
, pp. 1117-1127
-
-
Verstovsek, S.1
Kantarjian, H.2
Mesa, R.A.3
-
87
-
-
84863393110
-
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
-
Verstovsek S., Mesa R. A., Gotlib J., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med: 2012; 366 9 799 807
-
(2012)
N Engl J Med
, vol.366
, Issue.9
, pp. 799-807
-
-
Verstovsek, S.1
Mesa, R.A.2
Gotlib, J.3
-
88
-
-
84857837774
-
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
-
Harrison C., Kiladjian J. J., Al-Ali H. K., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med: 2012; 366 9 787 798
-
(2012)
N Engl J Med
, vol.366
, Issue.9
, pp. 787-798
-
-
Harrison, C.1
Kiladjian, J.J.2
Al-Ali, H.K.3
-
89
-
-
79952333359
-
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
-
Pardanani A., Gotlib J. R., Jamieson C., et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol: 2011; 29 7 789 796
-
(2011)
J Clin Oncol
, vol.29
, Issue.7
, pp. 789-796
-
-
Pardanani, A.1
Gotlib, J.R.2
Jamieson, C.3
-
90
-
-
69249192267
-
-
ASH Annual Meeting Abstracts. November 16
-
Moliterno A. R., Roboz G. J., Carroll M., Luger S., Hexner E., Bensen-Kennedy D. M. An open-label study of CEP-701 in patients with JAK2 V617F-positive polycythemia vera and essential thrombocytosis. ASH Annual Meeting Abstracts. November 16,: 2008; 112 11 99
-
(2008)
An Open-label Study of CEP-701 in Patients with JAK2 V617F-positive Polycythemia Vera and Essential Thrombocytosis
, vol.112
, Issue.11
, pp. 99
-
-
Moliterno, A.R.1
Roboz, G.J.2
Carroll, M.3
Luger, S.4
Hexner, E.5
Bensen-Kennedy, D.M.6
-
91
-
-
0037775584
-
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
-
Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators
-
Lee A. Y., Levine M. N., Baker R. I., et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med: 2003; 349 2 146 153
-
(2003)
N Engl J Med
, vol.349
, Issue.2
, pp. 146-153
-
-
Lee, A.Y.1
Levine, M.N.2
Baker, R.I.3
-
92
-
-
42949153260
-
Heparin-induced thrombocytopenia in myeloproliferative disorders: A rare or under-diagnosed complication
-
Spectre G., Kalish Y., Schliamser L., Varon D. Heparin-induced thrombocytopenia in myeloproliferative disorders: a rare or under-diagnosed complication? Am J Hematol: 2008; 83 5 420 423
-
(2008)
Am J Hematol
, vol.83
, Issue.5
, pp. 420-423
-
-
Spectre, G.1
Kalish, Y.2
Schliamser, L.3
Varon, D.4
-
93
-
-
75649116507
-
Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis
-
Randi M. L., Tezza F., Scapin M., et al. Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis. Acta Haematol: 2010; 123 3 140 145
-
(2010)
Acta Haematol
, vol.123
, Issue.3
, pp. 140-145
-
-
Randi, M.L.1
Tezza, F.2
Scapin, M.3
-
94
-
-
0025048792
-
A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders
-
Wehmeier A., Fricke S., Scharf R. E., Schneider W. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur J Haematol: 1990; 45 4 191 197
-
(1990)
Eur J Haematol
, vol.45
, Issue.4
, pp. 191-197
-
-
Wehmeier, A.1
Fricke, S.2
Scharf, R.E.3
Schneider, W.4
-
95
-
-
0018163875
-
Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors
-
Kaywin P., McDonough M., Insel P. A., Shattil S. J. Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. N Engl J Med: 1978; 299 10 505 509
-
(1978)
N Engl J Med
, vol.299
, Issue.10
, pp. 505-509
-
-
Kaywin, P.1
McDonough, M.2
Insel, P.A.3
Shattil, S.J.4
-
96
-
-
0024403073
-
Platelet membrane abnormalities in myeloproliferative disorders: Decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function
-
Mazzucato M., De Marco L., De Angelis V., De Roia D., Bizzaro N., Casonato A. Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol: 1989; 73 3 369 374
-
(1989)
Br J Haematol
, vol.73
, Issue.3
, pp. 369-374
-
-
Mazzucato, M.1
De Marco, L.2
De Angelis, V.3
De Roia, D.4
Bizzaro, N.5
Casonato, A.6
-
97
-
-
0032530687
-
Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera
-
Le Blanc K., Lindahl T., Rosendahl K., Samuelsson J. Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. Thromb Res: 1998; 91 6 287 295
-
(1998)
Thromb Res
, vol.91
, Issue.6
, pp. 287-295
-
-
Le Blanc, K.1
Lindahl, T.2
Rosendahl, K.3
Samuelsson, J.4
-
98
-
-
0029951483
-
The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count
-
van Genderen P. J., Budde U., Michiels J. J., van Strik R., van Vliet H. H. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol: 1996; 93 4 962 965
-
(1996)
Br J Haematol
, vol.93
, Issue.4
, pp. 962-965
-
-
Van Genderen, P.J.1
Budde, U.2
Michiels, J.J.3
Van Strik, R.4
Van Vliet, H.H.5
-
99
-
-
0031472388
-
Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: Normalization after cytoreduction of the increased platelet count
-
van Genderen P. J., Prins F. J., Lucas I. S., et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. Br J Haematol: 1997; 99 4 832 836
-
(1997)
Br J Haematol
, vol.99
, Issue.4
, pp. 832-836
-
-
Van Genderen, P.J.1
Prins, F.J.2
Lucas, I.S.3
-
100
-
-
0022349805
-
The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: An analysis of 129 cases
-
Buss D. H., Stuart J. J., Lipscomb G. E. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol: 1985; 20 4 365 372
-
(1985)
Am J Hematol
, vol.20
, Issue.4
, pp. 365-372
-
-
Buss, D.H.1
Stuart, J.J.2
Lipscomb, G.E.3
-
101
-
-
84859650006
-
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
-
Finazzi G., Carobbio A., Thiele J., et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia: 2012; 26 4 716 719
-
(2012)
Leukemia
, vol.26
, Issue.4
, pp. 716-719
-
-
Finazzi, G.1
Carobbio, A.2
Thiele, J.3
|